P028: Switching treatment to cipaglucosidase alfa+miglustat positively affects motor function and quality of life in patients with late-onset Pompe disease

類似資料

• Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease
  著者:: Priya S. Kishnani, 等
  出版事項: (2024-11-01)
• Cipaglucosidase alfa plus miglustat: linking mechanism of action to clinical outcomes in late-onset Pompe disease
  著者:: Barry J. Byrne, 等
  出版事項: (2024-10-01)
• Corrigendum: Cipaglucosidase alfa plus miglustat: linking mechanism of action to clinical outcomes in late-onset Pompe disease
  著者:: Barry J. Byrne, 等
  出版事項: (2025-01-01)
• Improved Enzyme Replacement Therapy with Cipaglucosidase Alfa/Miglustat in Infantile Pompe Disease
  著者:: Lina Fiege, 等
  出版事項: (2023-08-01)
• 20947. ANÁLISIS DEL TAMAÑO DEL EFECTO DE CIPAGLUCOSIDASA ALFA MÁS MIGLUSTAT FRENTE A ALGLUCOSIDASA-ALFA EN ADULTOS CON ENFERMEDAD DE POMPE DE INICIO TARDÍO PRETRATADOS CON TERAPIA DE SUSTITUCIÓN ENZIMÁTICA
  著者:: A. Aguinaga-Barrilero, 等
  出版事項: (2024-11-01)